Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLAU | P00749 | 3/20 | 0.52 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.52 |
| ▸ | F12 | P00748 | 1/20 | 0.52 |
| ▸ | NCF1 | P14598 | 1/20 | 0.52 |
| ▸ | NOS3 | P29474 | 1/20 | 0.52 |
| ▸ | NOS1 | P29475 | 1/20 | 0.52 |
| ▸ | NOS2 | P35228 | 1/20 | 0.52 |
| ▸ | BACE1 | P56817 | 1/20 | 0.52 |
| ▸ | CA2 | P00918 | 5/20 | 0.50 |
| ▸ | CA1 | P00915 | 3/20 | 0.50 |
| ▸ | CA9 | Q16790 | 3/20 | 0.50 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | PLG | P00747 | 2/20 | 0.43 |
| ▸ | CA12 | O43570 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.41 |
| ▸ | PLAT | P00750 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29482553 | 1.00 | PLAU (0.52) | PLAUCYP2A6F12NCF1NOS3 | |
| Thiophene SCHEMBL3277367 | 0.90 | PLAU (0.43) | PLAUCYP2A6F12NCF1NOS3 | |
| SCHEMBL29277533 | 0.84 | CYP2A6 (0.55) | PLAUCYP2A6F12NCF1NOS3 | |
| SCHEMBL329993 | 0.82 | CYP2A6 (0.53) | PLAUCYP2A6F12NCF1NOS3 | |
| SCHEMBL10401348 | 0.82 | CYP2A6 (0.59) | PLAUCYP2A6F12NCF1NOS3 | |
| SCHEMBL4729572 | 0.81 | PLAU (0.44) | PLAUCYP2A6F12NCF1NOS3 | |
| SCHEMBL5610261 | 0.81 | CYP2A6 (0.52) | PLAUCYP2A6F12NCF1NOS3 | |
| SCHEMBL329994 | 0.81 | CYP2A6 (0.52) | PLAUCYP2A6F12NCF1NOS3 | |
| SCHEMBL29797287 | 0.81 | CYP2A6 (0.52) | PLAUCYP2A6F12NCF1NOS3 | |
| SCHEMBL1052021 | 0.81 | CYP2A6 (0.52) | PLAUCYP2A6F12NCF1NOS3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 650 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4709477-A2 | COMPOSITIONS AND METHODS FOR THE DIAGNOSIS AND TREATMENT OF MICROVASCULATURE DYSFUNCTION AND RELATED DISEASES | The Texas A&M University System (US) | 2026-03-18 | — | — | EP | claimed |
| WO-2024238454-A2 | COMPOSITIONS AND METHODS FOR THE DIAGNOSIS AND TREATMENT OF MICROVASCULATURE DYSFUNCTION AND RELATED DISEASES | THE TEXAS A&M UNIVERSITY SYSTEM (US) | 2024-11-21 | — | — | WO | claimed |
| US-20240299409-A1 | TREATMENT OF CEREBRAL CAVERNOUS MALFORMATIONS AND CEREBRAL ANEURYSMS WITH RHO KINASE INHIBITORS | BioAxone BioSciences, Inc. (US) | 2024-09-12 | — | — | US | claimed |
| CN-116196312-A | Fas receptor and application thereof | 徐州医科大学附属医院 | 2023-06-02 | — | — | CN | claimed |
| CN-113072494-B | Excited state adjustable isoquinoline sulfonamide functional molecular material and preparation and application thereof | 湖南大学 | 2022-06-07 | — | — | CN | claimed |
| US-20210290635-A1 | TREATMENT OF CEREBRAL CAVERNOUS MALFORMATIONS AND CEREBRAL ANEURYSMS WITH RHO KINASE INHIBITORS | AEGIS THERAPEUTICS, LLC | 2021-09-23 | — | — | US | claimed |
| CN-113072494-A | Excited state adjustable isoquinoline sulfonamide functional molecular material and preparation and application thereof | 湖南大学 | 2021-07-06 | — | — | CN | claimed |
| WO-2020168106-A1 | COMBINATIONS OF AGONISTS OF PROTEIN KINASE C WITH STEROIDS OR RETINOIC ACIDS FOR THE TREATMENT OF CANCER | Notable Labs, Inc. (US) | 2020-08-20 | — | — | WO | claimed |
| US-20190298733-A1 | TREATMENT OF CEREBRAL CAVERNOUS MALFORMATIONS AND CEREBRAL ANEURYSMS WITH RHO KINASE INHIBITORS | AEGIS THERAPEUTICS, LLC | 2019-10-03 | — | — | US | claimed |
| US-20170246181-A1 | TREATMENT OF CEREBRAL CAVERNOUS MALFORMATIONS AND CEREBRAL ANEURYSMS WITH RHO KINASE INHIBITORS | AEGIS THERAPEUTICS, LLC | 2017-08-31 | — | — | US | claimed |
| EP-1074545-A1 | ISOQUINOLINESULFONAMIDE DERIVATIVES AND DRUGS CONTAINING THE SAME AS THE ACTIVE INGREDIENT | Hidaka, Hiroyoshi (JP) | 2001-02-07 | — | — | EP | claimed |
| EP-0956865-A1 | MEDICINES COMPRISING Rho KINASE INHIBITOR | YOSHITOMI PHARMACEUTICAL INDUSTRIES, LTD. (JP) | 1999-11-17 | — | — | EP | claimed |
| CN-1233188-A | Medicines comprising Rho kinase inhibitor | YOSHITOMI PHARMACEUTICAL (JP) | 1999-10-27 | — | — | CN | claimed |
| US-5747507-A | MYOCARDIAL DISEASE | ASAHI KASEI KOGYO KABUSHIKI KAISHA (JP) | 1998-05-05 | — | — | US | claimed |
| EP-0783292-A1 | INHIBITION OF HAIR GROWTH | HANDELMAN, Joseph H. (US) | 1997-07-16 | — | — | EP | claimed |
| US-5554608-A | INHIBITOR OF PROTEIN KINASE C | GILLETTE COMPANY, THE, A DELAWARE CORPORATION | 1996-09-10 | — | — | US | claimed |
| WO-1996009806-A2 | INHIBITION OF HAIR GROWTH | HANDELMAN, JOSEPH, H. (US) | 1996-04-04 | — | — | WO | claimed |
| EP-0654266-A1 | CARDIAC PROTECTIVE | Asahi Kasei Kogyo Kabushiki Kaisha (JP) | 1995-05-24 | — | — | EP | claimed |
| US-5081246-A | Isoquinolino sulfonamino derivatives | Hidaka, Hiroyoshi (JP) | 1992-01-14 | — | — | US | claimed |
| US-4943581-A | CARDIOVASCULAR DISORDERS | HOKURIKU PHARMACEUTICAL CO., LTD. (JP) | 1990-07-24 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170246181-A1 | TREATMENT OF CEREBRAL CAVERNOUS MALFORMATIONS AND CEREBRAL ANEURYSMS WITH RHO KINASE INHIBITORS | ROCK2, ROCK1, CIT | PLAU 745/4885CYP2A6 4789/4885F12 1167/4885 |
| US-20240299409-A1 | TREATMENT OF CEREBRAL CAVERNOUS MALFORMATIONS AND CEREBRAL ANEURYSMS WITH RHO KINASE INHIBITORS | ROCK2, ROCK1, CIT | PLAU 745/4885CYP2A6 4789/4885F12 1167/4885 |
| US-20210290635-A1 | TREATMENT OF CEREBRAL CAVERNOUS MALFORMATIONS AND CEREBRAL ANEURYSMS WITH RHO KINASE INHIBITORS | ROCK2, ROCK1, CIT | PLAU 745/4885CYP2A6 4789/4885F12 1167/4885 |
| US-20190298733-A1 | TREATMENT OF CEREBRAL CAVERNOUS MALFORMATIONS AND CEREBRAL ANEURYSMS WITH RHO KINASE INHIBITORS | ROCK2, ROCK1, CIT | PLAU 745/4885CYP2A6 4789/4885F12 1167/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.